新生儿Fc受体(neonatal Fc receptor,FcRn)通过与免疫球蛋G(immunoglobulin G,IgG)结合,延长其半衰期并促进再循环,是维持血清IgG稳态的重要受体。然而,致病性IgG的异常积累与多种神经免疫性疾病的发生密切相关。FcRn拮抗剂通过阻断FcRn...新生儿Fc受体(neonatal Fc receptor,FcRn)通过与免疫球蛋G(immunoglobulin G,IgG)结合,延长其半衰期并促进再循环,是维持血清IgG稳态的重要受体。然而,致病性IgG的异常积累与多种神经免疫性疾病的发生密切相关。FcRn拮抗剂通过阻断FcRn与IgG的结合,可显著降低致病性IgG水平,从而有效地缓解相关疾病的临床症状。FcRn拮抗剂作为一种新兴的靶向治疗药物,展示了其治疗IgG介导的神经免疫性疾病的潜力。本文对FcRn拮抗剂的作用机制、种类和临床研究进展进行总结,以期为IgG介导的神经免疫性疾病的精准治疗提供新思路。未来的研究应重点关注药物的长期安全性、适应证拓展及个体化治疗策略,以进一步提升其临床应用价值。展开更多
Myasthenia gravis is an acquired,humoral immunity-mediated autoimmune disease characterized by the production of autoantibodies that impair synaptic transmission at the neuromuscular junction.The intervention-mediated...Myasthenia gravis is an acquired,humoral immunity-mediated autoimmune disease characterized by the production of autoantibodies that impair synaptic transmission at the neuromuscular junction.The intervention-mediated clearance of immunoglobulin G(IgG)was shown to be effective in controlling the progression of the disease.The neonatal Fc receptor(FcRn)plays a key role in prolonging the serum half-life of IgG.Antagonizing FcRn to prevent its binding to IgG can accelerate the catabolism of the latter,resulting in decreased levels of IgG,including pathogenic autoantibodies,thereby achieving a therapeutic effect.In this review,we detail the substantial research progress,both basic and clinical,relating to the use of FcRn inhibitors in the treatment of myasthenia gravis.展开更多
文摘新生儿Fc受体(neonatal Fc receptor,FcRn)通过与免疫球蛋G(immunoglobulin G,IgG)结合,延长其半衰期并促进再循环,是维持血清IgG稳态的重要受体。然而,致病性IgG的异常积累与多种神经免疫性疾病的发生密切相关。FcRn拮抗剂通过阻断FcRn与IgG的结合,可显著降低致病性IgG水平,从而有效地缓解相关疾病的临床症状。FcRn拮抗剂作为一种新兴的靶向治疗药物,展示了其治疗IgG介导的神经免疫性疾病的潜力。本文对FcRn拮抗剂的作用机制、种类和临床研究进展进行总结,以期为IgG介导的神经免疫性疾病的精准治疗提供新思路。未来的研究应重点关注药物的长期安全性、适应证拓展及个体化治疗策略,以进一步提升其临床应用价值。
基金supported by the National Natural Science Foundation of China,No.U1604181the Joint Project of Medical Science and Technology Research Program of Henon Province,No.LHGJ20190078+1 种基金Henan Medical Education Research Project,No.Wjlx2020531Henan Province Key R&D and Promotion Special Project(Science and Technology Tackle),No.212102310834(all to JW)。
文摘Myasthenia gravis is an acquired,humoral immunity-mediated autoimmune disease characterized by the production of autoantibodies that impair synaptic transmission at the neuromuscular junction.The intervention-mediated clearance of immunoglobulin G(IgG)was shown to be effective in controlling the progression of the disease.The neonatal Fc receptor(FcRn)plays a key role in prolonging the serum half-life of IgG.Antagonizing FcRn to prevent its binding to IgG can accelerate the catabolism of the latter,resulting in decreased levels of IgG,including pathogenic autoantibodies,thereby achieving a therapeutic effect.In this review,we detail the substantial research progress,both basic and clinical,relating to the use of FcRn inhibitors in the treatment of myasthenia gravis.
